Myelodysplastic Syndrome Treatment Market Size, Share, Trend, Outlook, Future Growth Analysis And Synthesis By 2025 Myelodysplastic (MDS) syndrome is a type of bone marrow disorder, where bone marrow is unable to produce healthy and mature blood cells. The immature blood cells called as blasts, get stored in the bone marrow and blood and obstruct the natural function of the hematological system which results in depletion of healthy red blood cells, platelets, and white blood cells. Myelodysplastic syndrome is usually seen in geriatric population and more often in older men than women. This syndrome is characterized by certain chromosomal mutations in Janus Kinase gene which include deletion of q arm in one or more chromosomes and complete deletion of chromosome 5 or 7 and an extra copy of chromosome 8. There are various types of myelodysplastic syndrome such as refractory cytopenia with unilineage dysplasia and refractory anemia with ringed sideroblasts among others. Approved drugs for MDS include Vidaza (Azacitidine), Revlimid (Lenalidomide), Decitabine (Dacogen), and Deferasirox (Jadenu). Revlimid (Lenalidomide) patent for MDS indication will be expiring in 2023. A number of generic azacitidine-based products for MDS are launched in the global market. Get In-Depth Sample Copy @ https://www.coherentmarketinsights.com/insight/request-sample/775 Rising implications associated with myelodysplastic syndrome are expected to affect the myelodysplastic syndrome treatment market According to the American Cancer Society, the incidence rate for myelodysplastic syndrome is 13,000 new cases each year which happens at a rate of 4.8 cases per 100,000 people. This trend is heavily affected or rather influenced by the average age of the population which, according to the World Health Organization (WHO), is increasing and is expected to double from 12% to 22% between 2015 and 2050. Furthermore, according to the American Society of Clinical Oncology (ASCO), age plays an important role in the occurrence of myelodysplastic syndrome as most of the people diagnosed with the disease are of age 65 and older. These factors are expected to boost the myelodysplastic syndrome treatment. The global myelodysplastic syndrome treatment market was valued at US$ 2,213.2 million in 2017 and is expected to witness a CAGR of 12.7% during the forecast period (2017 – 2025). Endeavor to introduce highly effective therapies for various MDS types would support the market growth Major pharmaceutical organizations such as Celgene are investing major amounts in research and development of MDS specific drugs and many of their drugs are showing potential in the clinical trials as shown in the table no.1. Furthermore, in 2016, Opsona Therapeutics Ltd. received orphan drug designation for its OPN-305 humanized IgG4 monoclonal antibody for MDS treatment. Also, after Celgene lost its U.S. exclusivity for Vidaza, many generic formulations have entered in the market for Vidaza and Natco Pharma is also expected to launch generic version of Vidaza in 2017, which will further boost myelodysplastic syndrome treatment market. Report includes chapters which deeply display the following deliverable about industry : • Myelodysplastic Syndrome Treatment Market Research Objective and Assumption • Myelodysplastic Syndrome Treatment Market Purview - Report Description, Executive Summary, and Coherent Opportunity Map (COM) • Myelodysplastic Syndrome Treatment Market Dynamics, Regulations, and Trends Analysis Market Dynamics, Regulatory Scenario, Industry Trend, Merger and Acquisitions, New system Launch/Approvals, Value Chain Analysis, Porter’s Analysis, and PEST Analysis • Global Myelodysplastic Syndrome Treatment Market, By Regions • Myelodysplastic Syndrome Treatment Market Competition by Manufacturers including Production, Share, Revenue, Average Price, Manufacturing Base Distribution, Sales Area and Product Type. • Myelodysplastic Syndrome Treatment Market Manufacturers Profiles/Analysis including Company Basic Information, Manufacturing Base and Its Competitors. • Myelodysplastic Syndrome Treatment Market Manufacturing Cost Analysis including Key Raw Materials and Key Suppliers of Raw Materials. • Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials Sourcing and Downstream Buyers • Marketing Strategy Analysis, Distributors/Traders including Marketing Channel, Market Positioning and Distributors/Traders List. • Market Effect Factors Analysis including Technology Progress/Risk, Consumer Needs/Customer Preference Change and Economic/Political Environmental Change. • Myelodysplastic Syndrome Treatment Market Forecast including Production, Consumption, Import and Export Forecast by Type, Applications and Region. • Research Findings and Conclusion Global Key Players Key players operating in the myelodysplastic syndrome treatment market include Celgene, Novartis, and Otsuka. Some of the other market players are Astellas, Astex, Acceleron Pharma, Onconova Pharmaceuticals, GlaxoSmithKline, Eli-Lilly, and CTI Biopharma. Detailed Segmentation: Global Myelodysplastic syndrome treatment market, By Drug: • Azacitidine • Lenalidomide • Decitabine • Deferasirox Global Myelodysplastic syndrome treatment market, By Geography: • North America • Latin America • Europe • Asia Pacific • Middle East • Africa Browse In-Depth Analysis Research Report @ https://www.coherentmarketinsights.com/marketinsight/myelodysplastic-syndrome-treatment-market-775 About Coherent Market Insights Coherent Market Insights is a prominent market research and consulting firm offering actionready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity. Contact Us Mr. Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email: [email protected]

The global myelodysplastic syndrome treatment market was valued at US$ 2,213.2 million in 2017 and is expected to witness a CAGR of 12.7% during the forecast period 2017–2025.